<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00053118</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000269284</org_study_id>
    <secondary_id>RPCI-DS-00-03</secondary_id>
    <nct_id>NCT00053118</nct_id>
  </id_info>
  <brief_title>Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer</brief_title>
  <official_title>High Dose Carboplatin Combined With Oral VP-16 In The Treatment Of Pediatric CNS Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation&#xD;
      may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining chemotherapy with peripheral&#xD;
      stem cell transplantation in treating children who have central nervous system cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the feasibility of administering an outpatient protocol comprising high-dose&#xD;
           carboplatin with autologous stem cell support and etoposide in pediatric patients with&#xD;
           primary central nervous system malignancies.&#xD;
&#xD;
        -  Determine the maximum tolerated dose of carboplatin when administered in this regimen in&#xD;
           these patients.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is dose-escalation study of carboplatin.&#xD;
&#xD;
      Patients receive filgrastim (G-CSF) IV once daily for 6 days followed by a maximum of 5&#xD;
      apheresis sessions. If the target number of peripheral blood stem cells is not achieved, some&#xD;
      patients receive G-CSF and undergo apheresis as above after a 2-week rest.&#xD;
&#xD;
      At least 3 days after completion of G-CSF, patients receive high-dose carboplatin IV over 1&#xD;
      hour on day 1, stem cell reinfusion on day 3, G-CSF subcutaneously on days 4-18 and 43-61,&#xD;
      and oral etoposide 3 times daily on days 21-42. Treatment continues for a maximum of 4&#xD;
      courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of carboplatin until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed monthly for 1 year and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-15 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Actual">July 2004</completion_date>
  <primary_completion_date type="Actual">July 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">1</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Lymphoma</condition>
  <condition>Neuroblastoma</condition>
  <condition>Retinoblastoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>IV</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>IV</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>IV</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow ablation with stem cell support</intervention_name>
    <description>IV</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>IV</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed primary central nervous system malignancy&#xD;
&#xD;
          -  Recurrent, persistent, or progressive disease after at least 1 prior first-line&#xD;
             treatment regimen&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and under at initial diagnosis&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 8 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count greater than 750/mm^3&#xD;
&#xD;
          -  WBC greater than 2,500/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  No underlying myelodysplasia, stem cell disorder, or other inherent hematologic&#xD;
             synthetic defect&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Liver function tests less than 2 times normal OR&#xD;
&#xD;
          -  Absence of active hepatitis by liver biopsy&#xD;
&#xD;
          -  Bilirubin less than 1.5 mg/dL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Glomerular filtration rate greater than 60 mL/min by radionucleotide assay&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Ejection fraction at least 45%&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  Clinically normal pulmonary function (patients 5 years of age and under)&#xD;
&#xD;
          -  FEV_1 and FVC at least 50% (patients over 5 years of age) OR&#xD;
&#xD;
          -  Arterial blood gas normal and DLCO greater than 50%&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No mucositis or mucosal infection&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior systemic cytotoxic chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 6 months since prior radiotherapy to the pelvis or spine&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Jean Bambach, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>January 27, 2003</study_first_submitted>
  <study_first_submitted_qc>January 27, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2003</study_first_posted>
  <last_update_submitted>February 25, 2011</last_update_submitted>
  <last_update_submitted_qc>February 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Barbara Bambach, MD</name_title>
    <organization>Roswell Park Cancer Institute</organization>
  </responsible_party>
  <keyword>childhood central nervous system germ cell tumor</keyword>
  <keyword>childhood choroid plexus tumor</keyword>
  <keyword>childhood craniopharyngioma</keyword>
  <keyword>childhood grade I meningioma</keyword>
  <keyword>childhood grade II meningioma</keyword>
  <keyword>childhood grade III meningioma</keyword>
  <keyword>recurrent childhood brain stem glioma</keyword>
  <keyword>recurrent childhood cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>recurrent childhood ependymoma</keyword>
  <keyword>recurrent childhood medulloblastoma</keyword>
  <keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>recurrent retinoblastoma</keyword>
  <keyword>childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>childhood atypical teratoid/rhabdoid tumor</keyword>
  <keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Retinoblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

